Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
11C-L-deprenyl-D2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO4602522 Group 1 | EXPERIMENTAL | - |
| RO4602522 Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 11C-L-deprenyl-D2 | DRUG | Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total |
| RO4602522 | DRUG | Multiple doses of RO4602522 for 14 days |
Inclusion Criteria: General: * Adults between 50-80 years of age. Females must be of non-child-bearing potential or if of child-bearing potential must use an acceptable form of contraception * Body mass index (BMI) 18.0-32.0 kg/m2 inclusive Healthy volunteers: * Healthy, with no clinically relev...
Top 20 of 30 competitors
11C-L-deprenyl-D2 is an investigational positron emission tomography imaging agent being studied in Alzheimer's disease. It is a small molecule developed by Roche Holding AG under the ticker RHHBY. It is designed for use as a research imaging tool rather than as a therapeutic treatment, and it remains in Phase 1 clinical development.
11C-L-deprenyl-D2 is used as a PET imaging agent in Alzheimer's disease research. Roche studied it in patients with Alzheimer's disease and in healthy volunteers to evaluate its behavior as an imaging tracer. It is not a treatment for Alzheimer's disease and is not approved for clinical use.
11C-L-deprenyl-D2 is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the clinical study of the compound, registered as NCT01701089, titled A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers.
11C-L-deprenyl-D2 is in Phase 1 development. It is investigational and has not been approved by the FDA. Roche has completed one Phase 1 trial of the compound, and no active trials are currently listed for it.
11C-L-deprenyl-D2 has been studied in one completed Phase 1 trial, NCT01701089, titled A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers. The trial enrolled 17 participants in Sweden, included healthy volunteers, and used a controlled design without randomization or double blinding.